LXEO Company Profile and Key Details

LXEO has shown weak momentum, losing -10.59% over the past week and -24.22% over the past quarter, though year-to-date performance is down -26.89%. Short-term trend indicators are mixed aligned (SMA20 0.49%, SMA50 -15.23%, SMA200 6.27%). The stock’s 14-day RSI is 45.31 (neutral), while the ATR of 0.47 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -37.22% below its high and over 375.86% above its low. Average 10-day trading volume of 1.12 million shares is in line with the 3-month average of 1.14 million, indicating normal recent market interest.

Lexeo Therapeutics, Inc. Common Stock has 54.00 million shares outstanding. The public float is 29.38 million shares, elevated short interest at 10.72% of float. This equals 5.28 million shares. The short ratio is 13.36 days. Institutional investors hold 89.82% of the float. Insiders own 0.53%. Longitude Capital Partners IV, LLC holds 2.57 million shares, Omega Fund VI, L.P. has 2.16 million shares and Townsend Richard Nolan has 392.48 thousand shares. Over the past six months, insider transactions show net selling. They sold 16.88 thousand shares across 12 transactions.

Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO) closed at $7.41 USD, losing -$0.03 (-0.43%) from the previous close of $7.44. The stock is currently mid-range between its 52-week high and low $1.45 and $10.99. With a market capitalization of about $540.71 million, Lexeo Therapeutics, Inc. Common Stock is classified as a small-cap and shows higher-than-market volatility (beta ~1.80). Key stats such as the average daily volume over the past year has been around 1.17 million shares, volume is running light vs its 52-week average. Headquartered in New York City, None, Lexeo Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO R. Nolan Townsend, the company employs approximately 75 people and listed since November 03, 2023. Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases.

Lexeo Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.79. This means the shares are trading above this model’s fair value.

Lexeo Therapeutics, Inc. Common Stock generated EPS of -$2.70 over the past year. Five-year average earnings growth is -99.98%. Wall Street analysts project EPS growth of 24.04% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 7 Strong Buy ratings, 14 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $30.00 to $9.00. The high target offers 303.23% upside. The low target suggests 20.97% downside. The mean target is $18.76. This offers 152.15% upside. Lexeo Therapeutics, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -30.71%. The prior quarter beat by -6.25%. Over the last six quarters, Apple has recorded several small beats. These include -7.25% in August 12, 2024.

Lexeo Therapeutics, Inc. Common Stock (NASDAQ:LXEO) shares are down -26.89% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Lexeo Therapeutics, Inc. Common Stock trading at a premium to the broader market with a P/E of -4.28. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $20.17, suggesting 171.1% upside. Our AI forecast model points to short-term weakness (-0.67% over two weeks), a medium-term rise (96.77% over three months), and a longer-term gain (54.84% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Lexeo Therapeutics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -0.67%, with price expected at $7.39 by March 23, 2026, within a range of $7.07 to $7.74 3-Month Outlook: Projected rise of 96.77%, reaching $14.64 by June 05, 2026, with a range of $14.20 to $15.15. 1-Year Outlook: Projected gain of 54.84%, with price at $11.52 by March 09, 2027, within a range of $2.03 to $14.48.

Lexeo Therapeutics, Inc. Common Stock trades at a P/E ratio of -4.28, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.72 trading at moderately above to book value. The P/FCF stands at -5.01, also above market averages.